Marker Therapeutics MRKR 深 沪
已收盘 12-12 16:00:00 美东时间
1.47
+0.050
+3.52%
华盛通- 最 高1.48
- 今 开1.45
- 成交量 25.30万股
- 最 低 1.42
- 昨 收 1.42
- 总市值 1902.02万
- 52周最高 4.07
- 市盈率 静 --
- 换手率 1.96%
- 52周最低 0.8099
- 委 比 -75.36%
- 总股本 1293.89万
- 历史最高 99.00
- 量 比 0.78
- 振 幅 4.23%
- 历史最低 0.8099
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $10.
12-08 22:44
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.47) by 74.74 percent. This is a 53.85 percent increase over losses of $(0.26) per share
11-14 06:31
Marker Therapeutics To Present Data From Phase 1 APOLLO Study Investigating MT-601 In Patients With Relapsed B Cell Lymphomas At ASH 2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy dataMT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs)
11-03 22:30
Marker Therapeutics Announces First Patient Treated In OTS Program, With Encouraging Preliminary Safety Data
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatmentOTS product was well tolerated - safety data
10-06 19:33
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated its Off-the-Shelf (OTS) program for multi-antigen recognizing (MAR) T cells, with the first patient treated in the Phase 1 RAPID study. The OTS product targeting four tumor antigens demonstrated encouraging safety data with no treatment-related adverse events. The study focuses on patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), with potential expansion to other indications. The company ...
10-06 11:30
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Phase 1 APOLLO study of MT-601 shows 66% objective response rate in NHL patients, with 50% achieving complete response. The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities or ICANS. The study will expand to investigate MT-601 at the maximum dose in DLBCL patients who relapsed after or are ineligible for CAR-T therapy. A live webcast discussing the results will be held today.
08-26 11:00
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics' CEO, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The session will focus on the Company's MAR T cell platform and clinical developments. Investors can access the webcast via Marker's Investor Relations website.
07-30 12:00
Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor
06-17 20:08
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics collaborates with Cellipont Bioservices to manufacture MT-601, a Multi-Antigen Recognizing T cell therapy for lymphoma patients. MT-601 has shown promising results in the Phase 1 APOLLO study, with 78% of participants experiencing objective responses. The partnership aims to accelerate clinical supply and prepare for potential pivotal trials. Both companies emphasize their commitment to advancing innovative immunotherapies to ...
06-17 12:00
